ArticleESC heart failure2026
Sacubitrilat exerts potent antiarrhythmic effects through activation of natriuretic peptide receptor-C.
Article in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionSacubitril, a neprilysin inhibitor used in the treatment of heart failure, has been shown to exert direct antiarrhythmic effects on ventricular cardiomyocytes. However, the underlying mechanisms and molecular targets remain to be elucidated. This study, therefore, aimed at investigating the direct antiarrhythmic properties of sacubitril and exploring a potential involvement of natriuretic peptides in the context of arrhythmia-induced cardiomyopathy (AIC). METHODS AND
resultsDiastolic sarcoplasmic reticulum (SR) Ca2+ leak was induced in isolated murine ventricular cardiomyocytes by enhancing late sodium current with ATX-II, and in human induced pluripotent stem cell-derived ventricular cardiomyocytes (iPSC-CM) by 24-h tachyarrhythmic stimulation. Diastolic Ca2+ leak and Ca2+ transient kinetics were quantified using confocal and epifluorescence microscopy, while pharmacological tools (CNP, ANP, NPR-C agonist cANP4-23, and NPR-C blocker osteocrin) dissected receptor involvement. In silico modelling explored potential binding sites of sacubitrilat to NPR-C. CNP, but not ANP, reversed the increases in Ca2+ spark frequency induced by ATX-II in murine ventricular cardiomyocytes. This effect was reproduced by selective NPR-C activation with cANP4-23 and abolished by NPR-C blockade with osteocrin. In a similar manner, sacubitrilat suppressed pathological SR Ca2+ leak in both murine and human iPSC-derived cardiomyocytes. This protection was fully lost when NPR-C was inhibited. Sacubitrilat did not cause any significant alterations in systolic Ca2+ release and SR Ca2+ load in murine ventricular cardiomyocytes. In silico modelling identified a plausible hydrophobic binding pocket for sacubitrilat at the NPR-C dimer, thus supporting a direct receptor interaction.
conclusionsThese data indicate that activation of NPR-C is both necessary and sufficient for the potent antiarrhythmic actions of sacubitrilat, mediating a selective reduction of arrhythmogenic SR Ca2+ leak in murine ventricular cardiomyocytes as well as in a cellular model of human AIC in iPSC-CM. NPR-C therefore emerges as a promising molecular target for the development of novel antiarrhythmic therapies suitable for patients with heart failure and arrhythmia-induced cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.